Hostname: page-component-cd9895bd7-gbm5v Total loading time: 0 Render date: 2024-12-26T07:06:46.842Z Has data issue: false hasContentIssue false
  • English
  • Français

Antidepressants in the 1990s

Published online by Cambridge University Press:  11 October 2011

Eugene S. Paykel
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorials
Information
Epidemiology and Psychiatric Sciences , Volume 9 , Issue 3 , September 2000 , pp. 152 - 155
Copyright
Copyright © Cambridge University Press 2000

References

REFERENCES

American Psychiatric Association (1993). Practice guidelines for major depressive disorder in adults. American Journal of Psychiatry 150, Suppl. 4, 1–26.CrossRefGoogle Scholar
Berman, R.M., Darnell, A.M., Miller, H.L., Anand, A. & Charney, D.S.. (1997). Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double blind, placebo-controlled trial. American Journal of Psychiatry 154, 37–43.Google ScholarPubMed
Blier, P., de Montigny, C. & Chaput, Y. (1987). Modifications of the serotonin system by antidepressant treatments: implications for the therapeutic response in major depression. Journal of Clinical Psychopharmacology 7, Suppl. 6, 245–355.CrossRefGoogle ScholarPubMed
Bordet, R., Thomas, P. & Dupuis, B. (1997). Effect of pindolol on onset of action of paroxetine in the treatment of major depression: intermediate analysis of a double-blind, placebo-controlled trial. American Journal of Psychiatry 155, 1346–1351.CrossRefGoogle Scholar
Brodaty, H., Harris, L., Peters, K., Wilhelm, K., Hidkie, I., Boyce, P., Mitchell, P., Parker, G. & Eyers, K. (1993). Prognosis of depression in the elderly: a comparison with younger patients. British Journal of Psychiatry 163, 589–596.CrossRefGoogle ScholarPubMed
Davidson, J., Pleton, S., Krishnan, R.R. & Allf, B. (1986). The Newcastle Anxiety Depression Index in relationship to the effects of MAOI and TCA drugs. Journal of Affective Disorders 11, 51–61.CrossRefGoogle Scholar
Den Boer, J.A. & Westenberg, H.G.M. (1988). Effect of serotonin and noradrenaline uptake inhibitors in panic disorders: a double-blind comparative study with fluvoxamine and maprotiline. International Journal of Clinical Psychopharmacology 3, 59–74.CrossRefGoogle Scholar
Evans, L., Kenardy, J., Schneider, P. & Hoey, H. (1986). Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. A double-blind comparison of zimeldine, imipramine and placebo. Acta Psychiatrica Scandinavica 73, 49–53.CrossRefGoogle ScholarPubMed
Faedda, G.L., Tondon, L., Baldessarini, R.J., Suppes, T. & Tohen, M. (1993). Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Archives of General Psychiatry 50, 448–455.CrossRefGoogle ScholarPubMed
Fava, G.A., Rafanelli, C., Grandi, S., Canestrari, R. & Morphy, M.A. (1998). Six year outcome for cognitive behavioural treatment of residual symptoms in major depression. American Journal of Psychiatry 155, 1443–1445.CrossRefGoogle ScholarPubMed
Goodman, W.K., Price, L.H., Delgado, P.L., Palumbo, J., Krystal, J.H., Nagy, L.M., Rasmussen, S.A., Heninger, G.R. & Charney, D.S. (1990). Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry 47, 577–585.CrossRefGoogle ScholarPubMed
Keller, M.B., Klerman, G.L., Lavori, P.W., Coryell, W., Endicott, J. & Taylor, J.. (1984). Long-term outcome of episodes of major depression: clinical and public health significance. Journal of the Ame-rican Medical Association 252, 788–792.CrossRefGoogle ScholarPubMed
Kiloh, L.G., Andrews, G.A. & Neilson, M. (1988). The long-term out-come of depressive illness. British Journal of Psychiatry 153, 752–757.CrossRefGoogle Scholar
Kramer, M.S., Cutler, N., Feighner, J., Shrivastava, R., Carman, J., Sramek, J.J., Reines, S.A., Liu, G., Snavely, D., Wyatt-Knowles, E., Hale, J.J., Mills, S.G., MacCoss, M., Swain, C.J., Harrison, T., Hill, R.G., Hefti, F., Scolnick, E.M., Cascieri, M.A., Chicchi, G.G., Smith, D., Carlson, E.J., Hargreaves, R.J. & Rupniak, N.M.J. (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281, 1640–1645.CrossRefGoogle ScholarPubMed
Kupfer, D.J. (1991). Long-term treatment of depression. Journal of Clinical Psychiatry 52, Suppl. May, 28–34.Google ScholarPubMed
Lee, A.S. & Murray, R.M.. (1988). The long-term outcome of Maudsley depressives. British Journal of Psychiatry 153, 741–751.CrossRefGoogle ScholarPubMed
Leonard, H., Swedo, S., Rapoport, J.L., Coffey, M. & Cheslow, D. (1988). Treatment of childhood obsessive-compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacological Bulletin 24, 93–95.Google ScholarPubMed
Liebowitz, W.R., Quitkin, F.M., Stewart, J.W., McGrath, P., Harrison, W.M., Markowitz, J.A., Rabkin, J.G., Tricamo, E., Goetz, D.M. & Klein, D.F. (1988). Antidepressant specificity in atypical depression. Archives of General Psychiatry 45, 129–137.CrossRefGoogle ScholarPubMed
Maes, M., Vandoolaeghe, E. & Desnyder, R. (1996). Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of Affective Disorders 41, 201–210.Google ScholarPubMed
Paykel, E.S. (1995). Clinical efficacy of reversible and selective inhibitors of monamine oxidase A in major depression. Acta Psychiatrica Scandinavica 91, Suppl. 386, 22–27.CrossRefGoogle Scholar
Paykel, E.S. (1996). Tertiary prevention: longer-term drug treatment in depression. In The Prevention of Mental Illness in Primary Care (ed. Kendrick, T., Tylee, A. and Freeling, P), pp. 281–293. Cambridge University Press: Cambridge.CrossRefGoogle Scholar
Paykel, E.S. & Priest, R.G. (1992). Recognition and management of depression in general practice: consensus statement. British Medical Journal 305, 1198–1202.CrossRefGoogle ScholarPubMed
Paykel, E.S., Ramana, R., Cooper, Z., Hayhurst, H., Kerr, J. & Barocka, A. (1995). Residual symptoms after partial remission: an important outcome in depression. Psychological Medicine 25, 1171–1180.CrossRefGoogle ScholarPubMed
Paykel, E.S., Rowan, P.R., Parker, R.R. & Bhat, A.V. (1982). Response to phenelzine and amitriptyline in subtypes of outpatient depression. Archives of General Psychiatry 39, 1041–1049.CrossRefGoogle ScholarPubMed
Paykel, E.S., Parker, R.R., Rowan, P.R., Rao, B.M. & Taylor, C.N. (1983). Nosology of atypical depression. Psychological Medicine 13, 131–139.CrossRefGoogle ScholarPubMed
Paykel, E.S., Hollyman, J.A., Freeling, P. & Sedgwick, P. (1988). Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial. Journal of Affective Disorders 14, 83–95.CrossRefGoogle ScholarPubMed
Paykel, E.S., Tylee, A., Wright, A., Priest, R.G., Rix, S. & Hart, D. (1997). The Defeat Depression Campaign: psychiatry in the public arena. American Journal of Psychiatry 154, Suppl. 6, 59–65.Google ScholarPubMed
Paykel, E.S., Hart, D. & Priest, R.G.. (1998). Changes in public attitudes to depression during the Defeat Depression Campaign. British Journal of Psychiatry 173, 519–522.CrossRefGoogle ScholarPubMed
Paykel, E.S., Scott, J., Teasdale, J.D., Johnson, A.L., Garland, A., Moore, R., Jenaway, A., Cornwall, P.L., Hayhurst, H., Abbott, R. & Pope, M. (1999). Prevention of relapse by cognitive therapy in residual depression: a controlled trial. Archives of General Psychiatry 56, 829–835.CrossRefGoogle ScholarPubMed
Perez, V., Gilaberte, I., Faries, D., Alvarez, E. & Artigas, F. (1997). Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349, 1594–1597.CrossRefGoogle ScholarPubMed
Perez, V., Soler, J., Puigdemont, D. & Alvarez, E. (1999). A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Archives of General Psychiatry 56, 375–379.CrossRefGoogle ScholarPubMed
Quitkin, F.M., Steward, J.W., McGrath, P.J., Liebowitz, J.R., Harrison, W.M., Tricamo, E., Klein, D.F., Rabkin, J.G., Wager, S. & Markowitz, J. (1988). Phenelzine versus imipramine in the treatment of probably atypical depression: defining syndrome boundaries of selective MAOI responders. American Journal of Psychiatry 145, 306–311.Google Scholar
Quitkin, F.M., McGrath, P.J., Stewart, J.W., Harrison, W., Tricamo, E., Wager, S.G., Ocepek-Welikson, K. & Nunes, E. (1990). Atypical depression, panic attacks and response to imipramine and phenelzine. Archives of General Psychiatry 47, 935–941.CrossRefGoogle ScholarPubMed
Ramana, R., Paykel, E.S., Surtees, P.G., Melzer, D. & Mehta, M. (1999). Medication received by patients with depression following the acute episode: adequacy and relation to outcome. British Journal of Psychiatry 174, 128–134.CrossRefGoogle ScholarPubMed
Ravaris, C.L., Robinson, D.S., Ives, J.O., Nies, A. & Bartlett, D. (1980). Phenelzine and amitriptyline in the treatment of depression. Archives of General Psychiatry 37, 1076–1080.CrossRefGoogle ScholarPubMed
Rosenbaum, J.F., Fava, M., Hong, S.L., Ascroft, R.C. & Krebs, W. (1998). Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biological Psychiatry 44, 77–87.CrossRefGoogle ScholarPubMed
Sasson, Y.Iancu, I., Fux, M., Taub, M., Dannon, P.N. & Zohar, J. (1999). A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. European Neuropsychopharmacology 9, 191–196.CrossRefGoogle ScholarPubMed
Sheehan, D., Ballenger, J. & Jacobsen, G. (1980). Treatment of endogenous anxiety with phobic, hysterical and hypochondriacal symptoms. Archives of General Psychiatry 36, 51–59.CrossRefGoogle Scholar
Smeraldi, E., Benedetti, F., Barbini, B., Campori, E. & Colombo, C. (1999). Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression: a placebo controlled trial. Neuropsychopharmacology 20, 380–385.CrossRefGoogle ScholarPubMed
Stewart, J.W., Quitkin, F., Liebowitz, M.R., McGrath, P.J., Harrison, W., & Klein, D.F. (1983). Efficacy of desipramine in depressed outpatients: response according to Research Diagnostic Criteria and severity of illness. Archives of General Psychiatry 40, 202–207.CrossRefGoogle ScholarPubMed
Suppes, T., Baldessarini, R.J., Faedda, G.L. & Tohen, M. (1991). Risk of recurrence following discontinuation of lithium treatment in bi-polar disorder. Archives of General Psychiatry 48, 1082–1088.CrossRefGoogle Scholar
Thoren, P., Asberg, M., Cronholm, B., Jornested, T.L. & Traskman, L. (1980). Clomipramine treatment of obsessive-compulsive disorder 1: a controled clinical trial. Archives of General Psychiatry 37, 1281–1285.CrossRefGoogle Scholar
Tome, M.B., Isaac, M.T. & Holland, C. (1997). Paroxetine and pindolol: a randomised trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. International Clinical Psychopharmacology 12, 81–89.CrossRefGoogle ScholarPubMed
West, E.D. & Dally, P.J. (1959). Effects of iproniazid in depressive syndromes. British Medical Journal 1, 1491–1499.CrossRefGoogle ScholarPubMed
Zanardi, R., Artigas, F., Franchini, L., Sforzini, L., Gasperini, M., Semraldi, E. & Perez, J. (1997). How long should pindolol be associated with paroxetine to improve the antidepressant response? Journal of Clinical Psychopharmacology 17, 446–450.CrossRefGoogle ScholarPubMed